-
Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells
2026-09-21
The reference study develops a phenotypic strategy for reducing SPP1 expression in tumor-associated macrophages by combining small-molecule screening with TAM-avid nanodelivery. Its lead formulation, CANDI460, lowered SPP1 in cellular and animal models and produced tumor remissions, providing a framework for therapeutically reprogramming tumor myeloid cells rather than broadly depleting them.
-
AMC-Hem Reveals New HO-1 Regulation
2026-09-21
The reference study introduces AMC-Hem, an aminocoumarin-based fluorescent substrate that enables real-time measurement and imaging of heme oxygenase-1 activity in living cells. Its application to human monocyte-derived macrophages linked HO-1 activity to lysosomal regions around phagocytosed erythrocytes and revealed non-transcriptional regulation by two small molecules.
-
Spatially Concentrated ABEs Correct PLP1 Mutations
2026-09-20
The reference study introduces spatially concentrated adenine base editors that improve pathogenic PLP1 correction in oligodendrocytes by locally enriching the TadA* deaminase near genomic targets. Its compact, AAV-compatible design combines stronger on-target editing with reduced transcriptome-wide RNA off-target activity, providing a mechanistic framework for difficult-to-edit myelinating cells.
-
o-Agatoxin IVA and Excitotoxicity in Cortical Neurons
2026-09-19
Lustig, Ahern, and Greenberg tested whether blocking P/Q-type calcium channels with α-agatoxin IVA protects cultured cortical neurons from excitotoxic injury. The toxin failed to reduce injury caused by veratridine, ouabain, or NMDA, showing that inhibition of depolarization-evoked glutamate release does not necessarily translate into neuroprotection.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-09-18
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different components of drug response. The work provides a practical framework for separating proliferation arrest from cell killing, improving interpretation of cancer drug screens and preclinical studies.
-
VER 155008: Mapping HSP70 Stress Biology
2026-09-17
VER 155008 is an adenosine-derived HSP 70 inhibitor that can be used to interrogate how chaperone activity shapes protein condensation, apoptosis, and cancer phenotypes. This article develops an assay strategy connecting Hsp70 ATPase inhibition with TDP-43 condensate biology while clearly separating established evidence from experimental hypotheses.
-
NSC-23766: Rac GTPase Inhibitor Workflows
2026-09-17
Build cleaner Rac1 loss-of-function experiments across breast cancer, endothelial barrier, and metabolic assays with NSC-23766 trihydrochloride. This workflow separates direct pathway inhibition from downstream effects and translates a new GPR81–FARP1–RAC1 glucose-uptake finding into testable assay designs.
-
Streptavidin-FITC for Mechanistic Assay Design
2026-09-16
Streptavidin-FITC can do more than reveal biotin: it can help separate molecular localization, cellular uptake, and functional delivery. This guide explains how to use fluorescein isothiocyanate conjugated streptavidin in mechanistically rigorous imaging, flow cytometry, and LNP-related workflows.
-
Entinostat (MS-275) Workflow for Cancer Research
2026-09-16
Build more informative Entinostat assays by separating growth arrest from cell killing and pairing viability with target-engagement measurements. This workflow connects HDAC1/3-focused pharmacology with cancer cell proliferation inhibition, retinoblastoma treatment research, and translational study design.
-
Dasatinib (BMS-354825) Research Workflows
2026-09-15
Build reproducible Src and Bcr-Abl signaling experiments with Dasatinib (BMS-354825), from phosphoprotein target engagement to migration and metastasis assays. This workflow also shows how to use the compound as a mechanistic comparator when studying EMT, cancer stem cell-like states, and the SNAI1–PIK3R2/p-EphA2 axis.
-
o-Agatoxin IVA and Excitotoxicity in Cortical Cultures
2026-09-15
Lustig, Ahern, and Greenberg tested whether blocking P- and Q-type voltage-gated calcium channels with ω-agatoxin IVA could protect cortical neurons from several excitotoxic insults. The study found no reduction in neuronal injury, showing that inhibition of presynaptic glutamate release does not necessarily translate into protection from downstream excitotoxic cell death.
-
Veratridine Workflows for Sodium Channel Assays
2026-09-14
Veratridine provides a controllable depolarization trigger for sodium channel dynamics research, excitotoxicity studies, and blocker screening. Its value also extends to chamber-specific cardiac models, where carefully validated right ventricular-like cardiomyocytes can reveal differences that mixed hPSC-cardiomyocyte populations obscure.
-
Carvedilol Phosphate: A New Lens on Hepatic IRI
2026-09-14
A translational framework for using Carvedilol Phosphate to interrogate adrenergic GPCR signaling, hepatocyte–macrophage crosstalk, and Arrb2-linked mechanisms in hepatic ischemia–reperfusion injury research.
-
Mifepristone (RU486) Workflows for Cancer Research
2026-09-13
Mifepristone (RU486) combines progesterone receptor blockade with a practical dose range for cancer, reproductive, and receptor-context experiments. This guide translates receptor heterogeneity into better controls, dose–response workflows, and troubleshooting decisions without overstating what the evidence proves.
-
DAPT in Hepatobiliary Organoid Research
2026-09-12
DAPT (GSI-IX) can turn hiPSC-derived hepatobiliary organoids into a mechanistic test system for γ-secretase and Notch signaling. This article connects staged organoid differentiation with causal pathway perturbation, functional readouts, formulation controls, and translational limitations.